Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC presents research on hepatitis C treatments in children and young people at the ISPOR conference in Dublin

Published: 15 November 2013

Results of a recently completed SHTAC project evaluating treatment for hepatitis C in children and young people were presented at a major international conference on health economics and outcomes research.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress, held at the Dublin Convention Centre during 4th - 6th November brought together leading experts from health economics and outcomes research, health decision makers and pharmaceutical and health technology developers. Dr Keith Cooper presented a poster on a recently-completed research project which assessed the cost effectiveness of peginterferon alfa and ribavirin for the treatment of hepatitis C in children and young people. The project, completed a systematic review and economic evaluation to investigate whether peginterferon alfa and ribavirin are clinically and cost effective for the treatment of hepatitis C in children and young people.  The research was commissioned by the NIHR Health Technology Assessment (HTA) programme on behalf of the National Institute for Health and Care Excellence (NICE) to inform NICE's appraisal of treatment of Hepatitis C in children.

For more information on SHTAC's research in hepatitis C please visit our Research page.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×